TrialBritish journal of haematology2015

REVEAL-1, a phase 2 dose regimen optimization study of vosaroxin in older poor-risk patients with previously untreated acute myeloid leukaemia.

Robert K Stuart et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.